terbinafine (topical)

General

Pronunciation:
ter-bin-a-feen


Trade Name(s)

  • Apo-Terbinafine Canadian Tradename
  • Lamisil AT
  • Novo-Terbinafine Canadian Tradename
  • PMS-Terbinafine Canadian Tradename

Ther. Class.
antifungals (topical)

Indications

Treatment of a variety of cutaneous fungal infections, including tinea pedis (athlete's foot), tinea cruris (jock itch), and tinea corporis (ringworm).

Action

Affects the synthesis of the fungal cell wall.

Therapeutic Effect(s):

Decrease in symptoms of fungal infection.

Pharmacokinetics

Absorption: Absorption through intact skin is minimal.

Distribution: Distribution after topical administration is primarily local.

Metabolism and Excretion: Highly metabolized; excreted in urine (primarily as metabolites).

Half-life: 21 hr.

TIME/ACTION PROFILE

ROUTEONSETPEAKDURATION
Topunknownunknownunknown

Contraindication/Precautions

Contraindicated in:

  • Hypersensitivity to active ingredients, additives, preservatives, or bases
  • Some products contain alcohol and should be avoided in patients with known intolerance.

Use Cautiously in:

  • Nail and scalp infections (may require additional systemic therapy)
  • OB: Lactation:Safety not established.

Adverse Reactions/Side Effects

Local: burning, itching, local hypersensitivity reactions, redness, stinging

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

Not known.

Route/Dosage

Topical: (Adults and Children ≥12 yr): Apply twice daily for 1 wk for tinea pedis. Apply once daily for 1 wk for tinea cruris or tinea corporis.

Availability (generic available)

Cream: 1%

Gel: 1%

Spray liquid: 1%

Assessment

  • Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.

Potential Diagnoses

Implementation

  • Consult physician or other health care professional for proper cleansing technique before applying medication.
  • Topical: Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by physician or other health care professional.

Patient/Family Teaching

  • Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes.
  • Caution patient that some products may stain fabric, skin, or hair. Check label information. Fabrics stained from cream can usually be cleaned by handwashing with soap and warm water.
  • Patients with athlete's foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
  • Advise patient to report increased skin irritation or lack of response to therapy to health care professional.

Evaluation/Desired Outcomes

Decrease in skin irritation and resolution of infection. Early relief of symptoms may be seen in 2–3 days.

terbinafine (topical) is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Learn more.

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - terbinafine (topical) ID - 109791 Y1 - 2019 PB - Davis's Drug Guide UR - https://anesth.unboundmedicine.com/anesthesia/view/Davis-Drug-Guide/109791/all/terbinafine__topical_ ER -